Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-08
2008-08-05
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S356100
Reexamination Certificate
active
07407981
ABSTRACT:
The present invention relates to the use of novel derivatives of general formula (I)in whichR3 is a (1-6C)alkyl, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO2R1, C(═NH)R1 or C(═NH)NR1 radical;R5, R6 and R7 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, OR8, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl, to treat a disease selected from the group consisting of: neurodegenerative diseases, strokes, cranial and spinal traumas and peripheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovaries syndrome, syndrome X, immunodeficiency and cancer.
REFERENCES:
patent: 6916956 (2005-07-01), Shinagawa et al.
patent: 6949579 (2005-09-01), Dutruc-Rosset et al.
patent: 7019011 (2006-03-01), Lesuisse et al.
patent: 7166629 (2007-01-01), Lesuisse et al.
patent: WO 02/22601 (2002-03-01), None
patent: WO 03/028720 (2003-04-01), None
Resnick et al., Targeting JNK3 for the treatment of neurodegenerative disorders, DDT, vol. 9, No. 21, Nov. 2004, especially pp. 932 and 936.
Vasudevan et al., Bioorg. Med. Chem. Lett., 15 (2005) 5293-5297, especially p. 5294.
Buee, L., et al., Tau Protein Isoforms, Phosphorylation and Role in Neurodegenerative Disorders, Brain Research Reviews vol. 33, (2000) pp. 95-130.
Hesse, et al., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neuroscience letters, 297, (2001) 187-190.
Hugon, et al., Toxic neuronal apoptosis and modifications of tau and APP gene and protein expressions., Drug metabolism reviews (1999), 31(3), 635-47.
Korneyev, Stress-induced tau phosphorylation in mouse strains with different brain Erk 1+2 immunoreactivity. ,Neurochemical Research (1998), 23(12), 1539-1543.
Babin Didier
Dutruc-Rosset Gilles
Halley Franck
Lesuisse Dominique
Rooney Thomas
Aventis Pharma S.A.
Chung Susannah
Gupta Balaram
Shameem Golam M. M.
LandOfFree
Aminoindazole derivatives as medicaments and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoindazole derivatives as medicaments and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoindazole derivatives as medicaments and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015215